About Carta Biosciences
Carta Biosciences is a company based in London (United Kingdom) founded in 2018 by Chee Yang Chen. It operates as a B2B. The company has 1 employees as of January 31, 2020. Carta Biosciences operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter London, United Kingdom
- Employees 1 as on 31 Jan, 2020
- Founders Chee Yang Chen
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Carta Biosciences Ltd
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
1
as on Jan 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Carta Biosciences
Detailed funding history for Carta Biosciences
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Carta Biosciences
Investment portfolio details for Carta Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Carta Biosciences
Detailed financials for Carta Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Carta Biosciences Comparisons
Peer comparison for Carta Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Carta Biosciences
Carta Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of Carta Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Carta Biosciences
Complete news archive for Carta Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Carta Biosciences
Carta Biosciences was founded in 2018.
Carta Biosciences is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Chee Yang Chen is the current CEO of Carta Biosciences. They have also founded this company.
As of Jan 31, 2020, the latest employee count at Carta Biosciences is 1.
Carta Biosciences, established in 2018, excels in providing healthcare solutions, advancing biotech innovations, focusing on genomic solutions, and fertility testing. Delivers comprehensive genomic testing solutions for in vitro fertilization procedures. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide.
Carta Biosciences's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.